Back

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors: pearls from recent trials and surveys Biomarkers ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Carly Adamson

Forth Valley Royal Hospital, Larbert (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study
Assistant Professor E. Maor (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial
Doctor A. Pandey (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors: pearls from recent trials and surveys

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Associations of baseline and changes in insulin-like growth factor binding protein-7 (IGFBP7) levels with heart failure: the PREVEND study
thumbnail
Congress Presentation
Diagnostic and prognostic performance of insulin-like growth factor-binding protein 7 in patients with acute dyspnea in the emergency department
thumbnail
Congress Presentation
Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources